PMID- 37631944
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230829
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 11
IP  - 8
DP  - 2023 Aug 17
TI  - A Comparative Study of Immunogenicity, Antibody Persistence, and Safety of Three 
      Different COVID-19 Boosters between Individuals with Comorbidities and the Normal 
      Population.
LID - 10.3390/vaccines11081376 [doi]
LID - 1376
AB  - Data on immunogenicity, immune response persistency, and safety of COVID-19 
      boosters in patients with comorbidities are limited. Therefore, we aimed to 
      evaluate three different boosters' immunogenicity and safety in individuals with 
      at least one underlying disease (UD) (obesity, hypertension, and diabetes 
      mellitus) with healthy ones (HC) who were primed with two doses of the BBIBP-CorV 
      vaccine and received a booster shot of the same priming vaccine or protein 
      subunit vaccines, PastoCovac Plus or PastoCovac. One hundred and forty subjects 
      including sixty-three ones with a comorbidity and seventy-seven healthy ones were 
      enrolled. The presence of SARS-CoV-2 antibodies was assessed before the booster 
      injection and 28, 60, 90, and 180 days after it. Moreover, the adverse events 
      (AEs) were recorded on days 7 and 21 postbooster shot for evaluating safety 
      outcomes. Significantly increased titers of antispike, antiRBD, and neutralizing 
      antibodies were observed in both UD and HC groups 28 days after the booster dose. 
      Nevertheless, the titer of antispike IgG and anti-RBD IgG was lower in the UD 
      group compared to the HC group. The long-term assessment regarding persistence of 
      humoral immune responses showed that the induced antibodies were detectable up to 
      180 days postbooster shots though with a declined titer in both groups with no 
      significant differences (p > 0.05). Furthermore, no significant difference in 
      antibody levels was observed between each UD subgroup and the HC group, except 
      for neutralizing antibodies in the hypertension subgroup. PastoCovac Plus and 
      PastoCovac boosters induced a higher fold rise in antibodies in UD individuals 
      than BBIBP-CorV booster recipients. No serious AEs after the booster injection 
      were recorded. The overall incidence of AEs after the booster injection was 
      higher in the UD group than the HC group among whom the highest systemic rate of 
      AEs was seen in the BBIBP-CorV booster recipients. In conclusion, administration 
      of COVID-19 boosters could similarly induce robust and persistent humoral immune 
      responses in individuals with or without UD primarily vaccinated with two doses 
      of the BBIBP-CorV. Protein-based boosters with higher a higher fold rise in 
      antibodies and lower AEs in individuals with comorbidities might be considered a 
      better choice for these individuals.
FAU - Ashrafian, Fatemeh
AU  - Ashrafian F
AUID- ORCID: 0000-0001-8260-100X
AD  - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran.
FAU - Bagheri Amiri, Fahimeh
AU  - Bagheri Amiri F
AUID- ORCID: 0000-0003-2943-2846
AD  - Department of Epidemiology and Biostatistics, Research Centre for Emerging and 
      Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran 1316943551, 
      Iran.
FAU - Bavand, Anahita
AU  - Bavand A
AD  - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran.
FAU - Zali, Mahsan
AU  - Zali M
AD  - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran.
FAU - Sadat Larijani, Mona
AU  - Sadat Larijani M
AUID- ORCID: 0000-0003-3681-5319
AD  - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran.
FAU - Ramezani, Amitis
AU  - Ramezani A
AUID- ORCID: 0000-0003-3502-8524
AD  - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran.
LA  - eng
GR  - 2127/Pasteur Institute of Iran/
PT  - Journal Article
DEP - 20230817
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC10459403
OTO - NOTNLM
OT  - COVID-19 vaccine
OT  - antibody persistence
OT  - booster
OT  - underlying diseases
COIS- The authors declare that they have no competing interest.
EDAT- 2023/08/26 10:46
MHDA- 2023/08/26 10:47
PMCR- 2023/08/17
CRDT- 2023/08/26 01:34
PHST- 2023/06/25 00:00 [received]
PHST- 2023/08/12 00:00 [revised]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/08/26 10:47 [medline]
PHST- 2023/08/26 10:46 [pubmed]
PHST- 2023/08/26 01:34 [entrez]
PHST- 2023/08/17 00:00 [pmc-release]
AID - vaccines11081376 [pii]
AID - vaccines-11-01376 [pii]
AID - 10.3390/vaccines11081376 [doi]
PST - epublish
SO  - Vaccines (Basel). 2023 Aug 17;11(8):1376. doi: 10.3390/vaccines11081376.